just parking
Press Release
SOURCE: Lexicon Genetics Incorporated
Lexicon Genetics Announces Issuance of OmniBank Functional Genomics Patent
Patent Covers a Powerful Resource for Defining Gene Function for Drug Discovery
THE WOODLANDS, Texas, Oct. 25 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today that it has been issued U.S. Patent No. 6,136,566 (the ``'566 patent'') entitled ``Indexed Library of Cells Containing Genomic Modifications and Methods of Making and Utilizing the Same.'' The '566 patent broadly covers commercial-scale collections of mutated ES cell clones such as those present in Lexicon's OmniBank library of over 90,000 mutated ES cell clones. The OmniBank library presently represents the world's most expansive genomics resource for using mammalian biology to determine the functional significance of the sequence data resulting from the Human Genome Project and other sequencing efforts. In addition, the '566 patent extends broad intellectual property protection for Lexicon's core technologies for determining the function of thousands of specific genes and applies to all of Lexicon's current gene trapping vectors and related methods.
``The '566 patent further confirms Lexicon's leadership position in technologies for discovering mammalian gene function for genome-wide pharmaceutical discovery,'' said Brian P. Zambrowicz, Ph.D., Lexicon's Senior Vice President of Genomics. ``Lexicon's proprietary genome-wide and gene-specific technologies will accelerate gene function discoveries for new therapeutic products.''
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Complementary to its gene-specific custom knockout technology, Lexicon has invented high-throughput genome-wide gene trapping technology to discover thousands of genes and expand its OmniBank® library of tens of thousands of knockout mouse clones. The Company uses an integrated platform of functional genomics technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. Lexicon's Internet exchange, www.lexgen.com, enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover pharmaceutical products based on genes and knowledge of their functions. Lexicon has established drug discovery collaborations with Abgenix, Inc. and Arena Pharmaceuticals, Inc., a LexVision(TM) collaboration with Bristol-Myers Squibb Company, and functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies, including American Home Products, Boehringer Ingelheim Pharmaceuticals, DuPont Pharmaceuticals Company, Millennium Pharmaceuticals, Inc., N.V. Organon, Pharmacia Corp. and The R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, as well as leading academic institutions worldwide. Additional Company information is available at www.lexicon-genetics.com . |
